MDT
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E, PEG, Graham Number
- Forward P/E (13.10) is lower than current P/E
- Price ($79.37) is significantly higher than Graham Number ($55.45)
- Price is far above Intrinsic Value ($25.06)
Ref Growth rates
- Positive revenue growth (8.7%)
- Negative earnings growth (-11.8%)
- PEG ratio of 1.43 suggests slight overpayment for growth
Ref Historical trends
- Consistent earnings beats over 25 quarters
- Poor 5-year return (-29.4%)
- Recent 6-month decline of -12.1%
Ref Altman Z-Score, Piotroski F-Score
- Low Debt/Equity (0.57)
- High Current Ratio (2.54)
- Piotroski F-Score of 4/9 indicates only stable health, not strength
Ref Yield, Payout
- Respectable yield of 3.58%
- High payout ratio (79.05%) limits room for dividend growth
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for MDT and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
MDT
Medtronic plc
Primary
|
-29.4% | -3.5% | -3.2% | -12.1% | -7.4% | -4.6% |
|
MCK
McKesson Corporation
Peer
|
+373.0% | +141.7% | +38.6% | +16.5% | +6.3% | -1.2% |
|
HCA
HCA Healthcare, Inc.
Peer
|
+225.1% | +111.6% | +37.9% | +22.4% | +12.5% | -0.8% |
|
GSK
GSK plc
Peer
|
+77.5% | +69.5% | +48.1% | +25.9% | +0.7% | -5.5% |
|
BMY
Bristol-Myers Squibb Company
Peer
|
+2.8% | -13.4% | -2.9% | +15.8% | +1.1% | -1.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q1 2026
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
MDT
Medtronic plc
|
NEUTRAL | $101.9B | 22.17 | 9.4% | 13.0% | $79.37 | |
|
MCK
McKesson Corporation
|
BULLISH | $104.45B | 26.32 | -% | 1.0% | $842.09 | Compare |
|
HCA
HCA Healthcare, Inc.
|
BULLISH | $108.0B | 18.28 | -% | 8.5% | $472.65 | Compare |
|
GSK
GSK plc
|
BULLISH | $108.22B | 14.42 | 43.3% | 17.5% | $54.22 | Compare |
|
BMY
Bristol-Myers Squibb Company
|
NEUTRAL | $111.25B | 18.46 | 33.8% | 12.6% | $54.65 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-20 | BLOMQUIST DENISE L | Officer | Gift | 340 | - |
| 2026-02-19 | KIIL HARRY SKIP | Officer | Sale | 52,524 | $5,132,217 |
| 2026-02-19 | KIIL HARRY SKIP | Officer | Option Exercise | 50,876 | $4,624,512 |
| 2025-11-20 | BLOMQUIST DENISE L | Officer | Gift | 170 | - |
| 2025-11-19 | SMITH GREGORY L | Officer | Sale | 30,000 | $3,058,451 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Medtronic's 10-Q filing dated February 24, 2026, outlines a broad range of operational and financial risks, though specific financial highlights were not provided in the excerpts. Key risks include intense industry competition, regulatory delays, supply chain interruptions, and pricing pressures. The company also notes potential volatility stemming from cybersecurity incidents, international armed conflicts, and currency exchange fluctuations.
Medtronic's 10-Q filing highlights significant operational risks, including intense medical device competition, regulatory delays, and supply chain interruptions. The company also notes potential financial headwinds from pricing pressures, currency fluctuations, inflation, and geopolitical instability affecting international operations.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning MDT from our newsroom.